NEWS ALERT
3 September 2025 | Geneva, Switzerland
Life-Saving DR-TB Treatments Even More Affordable Following Newest Bedaquiline Price Decrease
The Stop TB Partnership’s Global Drug Facility (GDF) has announced a 30% price reduction for bedaquiline produced by Lupin, now available at just $63 per treatment course. This latest decrease brings the lowest cost of the full BPaLM regimen—the most widely recommended treatment for drug-resistant tuberculosis (DR-TB)—below $300 for the first time, now priced at $284 per course.
The bedaquiline price cut is projected to generate over $4.5 million in annual savings for GDF clients and high-burden countries that reference GDF prices in their own procurement negotiations. Savings from this price reduction alone could enable the purchase of 71,000 additional bedaquiline courses or 16,000 full BPaLM treatment regimens each year.
This announcement follows two earlier price reductions in 2025:
Together, these are the third consecutive price reductions over a 6-month period by GDF for key DR-TB medicines, dramatically improving affordability and access.
In total, six WHO-recommended DR-TB regimens are now priced under $300—with the endTB 9BLMZ regimen dropping below $200 to just $173 per course.
“2025 brought a lot of challenges to us all, but we don’t give up on our work, efforts and ambition. And here we are, announcing the lowest price for DR-TB treatment regimens ever! In the current financial environment in which every penny matters, this is a huge achievement. Now, let’s go and diagnose and treat people with drug-resistant TB at historical levels as well, to match our ambition” said Dr Lucica Ditiu, Executive Director of the Stop TB Partnership.
Ani Herna Sari, a DR-TB survivor and advocate from Indonesia added “DR-TB is one of the most significant challenges I have ever faced. It was one of life and death. Unlike many in Indonesia and around the world, I ultimately overcame this challenge in spite of having to undertake over two years of treatment, toxic injectables and related side effects. As DR-TB survivors we celebrated the 2019 news recommending the use of BDQ as a core drug, replacing those toxic injectables that were features of my treatment. Now, as a DR TB survivor I again celebrate this price reduction. But I also recognize that with this news we must all work harder to ensure that now that this the drug is more affordable, that it is also accessible for all people who need it, that people can realise their right to health, can live with dignity and that more lives can be saved.”
Since BPaLM’s initial recommendation in December 2022, the cost of a 6-month BPaLM treatment course via GDF has dropped by 52%, from $588 to $284, despite an estimated global market size of only 123,000 people eligible for treatment with BPaLM.
“For more than two decades, GDF - as the leading global procurer of TB products - has collaborated with Lupin and other trusted suppliers. Along the way, GDF created innovative, purpose-built tools that institutionalize sustainable market interventions—helping to drive new product development, promote affordable pricing, and protect against supply chain instability in a fragile TB landscape”, noted Dr Brenda Waning, Chief of the Global Drug Facility.
“Lupin is proud to collaborate with The Global Drug Facility to make bedaquiline, an essential medicine in the fight against Multi Drug Resistance TB, more accessible and affordable for people with people with TB across the globe,” said Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus SBU, Lupin. He added, “the recent price reduction reflects our strong and deep-rooted commitment to delivering high-quality and affordable medicines to people with TB worldwide. Through this partnership, we reaffirm our dedication to people-centric innovation and equitable access, ensuring that countries burdened by TB have the necessary treatment options they need to save lives and strengthen public health systems’’.
For more information about these products, please refer to GDF Product Catalogs and Ordering Lists. For detailed information on regimen pricing, please refer to GDF TB Regimen Prices. For further support, please contact your GDF Country Supply Officer or email gdf@stoptb.org.
